Bruera E, Ripamonti C, Brenneis C, Macmillan K, Hanson J
Palliative Care Program, Edmonton General Hospital, Canada.
J Pain Symptom Manage. 1992 Apr;7(3):138-40. doi: 10.1016/s0885-3924(06)80004-7.
In a randomized, double-blind, crossover study, we evaluated the effect of intravenous lidocaine (5 mg/kg body weight over 30 min) on the neuropathic pain of advanced cancer patients. Pain intensity, assessed by a visual analogue scale, did not show any significant difference between lidocaine and placebo infusion. The blinded choice of patients and investigators also suggested no significant improvement from lidocaine when given by this regimen. Intravenous lidocaine does not appear to have a significant analgesic effect on neuropathic cancer pain.
在一项随机、双盲、交叉研究中，我们评估了静脉注射利多卡因（30分钟内5毫克/千克体重）对晚期癌症患者神经性疼痛的影响。通过视觉模拟量表评估的疼痛强度在利多卡因输注和安慰剂输注之间未显示出任何显著差异。患者和研究人员的盲法选择也表明，按此方案给予利多卡因时没有显著改善。静脉注射利多卡因似乎对神经性癌痛没有显著的镇痛作用。
